Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 20, 2014

View Archived Issues

Phase II results show vismodegib is well tolerated in patients with mPDA

Kissei gains approval for Savene in Japan

XBiotech launches phase II study in rare disorder pyoderma gangrenosum

AstraZeneca and Bristol-Myers Squibb Diabetes Alliance awards grant to ADA

Oryzon cleared to begin phase I/IIa trial of ORY-1001 in the U.K.

Researchers in the U.S. prepare new GWT1 inhibitors for fungal infections

Novel ALK/c-Met inhibitors disclosed by Concert Pharmaceuticals

Novel biomarkers for breast cancer prognosis identified and evaluated

Dart NeuroScience discloses novel PDE1B inhibitors

Inhibition of immune cell priming to ameliorate autoimmune inflammatory diseases

Scientists at Merck & Co. patent new SYK inhibitors

Development of a novel class of tau ligands for medical imaging of AD

Aniona prepares novel GABA(A) modulators

Researchers at Bristol-Myers Squibb design new monoclonal antibodies

NovoEight obtains Japanese approval

Giotrif approved in Japan for patients with NSCLC and EGFR mutation

FDA extends review of Trimel's NDA for CompleoTRT

Karyopharm targets PAK-4 in pancreatic cancer

Sovaldi approved in Europe for treatment of chronic HCV infection

Shire sells Dermagraft assets to Organogenesis

Kyowa Hakko Kirin obtains approval for new formulation of antiepileptic agent in Japan

Ariad's Iclusig now commercially available in U.S.

Acerta Pharma launches phase I trial of novel BTK inhibitor in CLL

Mitsubishi Tanabe files for use of Telavic in additional indication in Japan

Biocon launches biosimilar version of Herceptin in India

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...